UNH Stock Recent News

Dividend stocks that offer high yields can be gold mines for your portfolio as they can generate loads of recurring income for you for years. Whether you want to use the money to reinvest in those stocks or simply use the dividend income to help add to your cash position, they can make for great long-term investments to have.

Barclays analyst Andrew Mok raised the firm's price target on UnitedHealth to $362 from $337 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Barclays lowered the firm's price target on Molina Healthcare to $185 from $186 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 23 Oct

Barclays raised the firm's price target on Elevance Health to $373 from $327 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 11 Sep

Barclays analyst Andrew Mok raised the firm's price target on CVS Health to $87 from $80 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Barclays raised the firm's price target on Cigna to $383 from $354 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 30 Oct

Barclays analyst Andrew Mok lowered the firm's price target on Centene to $33 from $45 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

If you buy a stock that goes up 20% in a year, I'd say you made a good investment. After all, the S&P 500 (^GSPC 0.51%) returns somewhere around 10% annually on average.

UnitedHealth's stock is deeply undervalued after a tough 2025, but market pessimism exceeds the company's actual fundamentals. A major premium repricing cycle in 2026 should restore margins and profitability, positioning UnitedHealth for a strong recovery. Valuation multiples are at decade lows, free cash flow is robust, and the dividend yield is near record highs, making this an attractive entry point.

With its gain of 3.2%, the Dow Jones Industrial Average (^DJI -1.16%) outperformed most other major market indexes in August. Only a small handful of the Dow's constituents, however, did the bulk of this heavy lifting.